Research ArticleArticle
Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19
Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, Zheng Yang, Ragini Vuppugalla, Jeremy Hurley, Denise Thorndike, Andrew Wagner, Anjaneya Chimalakonda and A. David Rodrigues
Drug Metabolism and Disposition September 2012, 40 (9) 1698-1711; DOI: https://doi.org/10.1124/dmd.112.045575
Tatyana Zvyaga
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Shu-Ying Chang
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Cliff Chen
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Zheng Yang
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Ragini Vuppugalla
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Jeremy Hurley
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Denise Thorndike
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Andrew Wagner
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Anjaneya Chimalakonda
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
A. David Rodrigues
Lead Profiling (T.Z., J.H., D.T.), and Bioanalytical Technologies (A.W.), Bristol-Myers Squibb, Wallingford, Connecticut; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (S.-Y.C., C.C., Z.Y., R.V., A.C., A.D.R.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
PPIs AS INHIBITORS OF HUMAN P450s
Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, Zheng Yang, Ragini Vuppugalla, Jeremy Hurley, Denise Thorndike, Andrew Wagner, Anjaneya Chimalakonda and A. David Rodrigues
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1698-1711; DOI: https://doi.org/10.1124/dmd.112.045575
Research ArticleArticle
PPIs AS INHIBITORS OF HUMAN P450s
Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, Zheng Yang, Ragini Vuppugalla, Jeremy Hurley, Denise Thorndike, Andrew Wagner, Anjaneya Chimalakonda and A. David Rodrigues
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1698-1711; DOI: https://doi.org/10.1124/dmd.112.045575
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement